Paul J. van Diest

TL;DR: FANCD2 expression is absent in 10–20% of sporadic and BRCA1-related breast cancers, indicating that somatic inactivating (epi)genetic events in FAN CD2 may be important in both sporadic and hereditary breast carcinogenesis.

TL;DR: TMA technology appears to be a valid method for immunohistochemical analysis of molecular markers in ESCC provided that the staining pattern in the tumor is homogeneous.

TL;DR: Expression and amplification of EGFR are frequently observed in high-grade osteosarcomas and are associated with improved prognosis in a dose-responsive way, implying that low EGFR expression possibly predicts lack of response to conventional treatment inhigh-grade fractures and may warrant a more intensive therapeutic approach, although not based on EGFR targeting.

TL;DR: The proportion of BCs classified as luminal A-like is highly influenced by the Ki67-LI assessment method, which may have a direct effect on the proportion of patients considered having low-risk disease and thus influence therapeutic decision making.

TL;DR: A new polymerase chain reaction-based test, called multiplex ligation-dependent probe amplification (MLPA), is validated as a simple and quick method to simultaneously assess HER-2/neu and TopoIIα gene amplification status in paraffin-embedded breast cancer samples and thus an attractive supplement or alternative to CISH.